DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Tak Mak

Lewis Cantley

Craig Thompson

Shin-San Michael Su

Agios Pharmaceuticals, Inc.

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and other therapeutic areas. The company's pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.

Pierre Belichard

Stanislav Dusko EHRLICH

Enterome

DBV Technologies is a global clinical stage biopharmaceutical company that develops epicutaneous immunotherapy for food allergies and other immunological diseases. Self-described.

DBV Technologies

DBV Technologies | 16,493 followers on LinkedIn. On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™ | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.

We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.

This mission drives our commitment to the advancement of treatments for patients and their families.

Vincent DIOSZEGHY

LifeSci Advisors-LS Associates

Will de Groot

Freelance Photographer at Thomas Raffoux Photography

Thomas Raffoux

Chief Medical Officer at Sitryx Therapeutics

Ravi Rao

DBV is proud to sponsor FAACT, Food Allergy & Anaphylaxis Connection Team 's Digital Influencer Summit and tenth annual Global Food Industry and Research Summit. We look forward to connecting with peers to explore how to safely meet the needs of the #FoodAllergy community. Stop by our booth to learn more: https://bit.ly/40CQskp

Today, we reported financial results for the third quarter of 2024. Read the full press release here: https://bit.ly/4hEPzhe

We look forward to joining our #FoodAllergy peers at the upcoming American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, where we will be hosting a product theater on Saturday, October 26. Visit us at our booth to learn more about our potential treatment for those with peanut allergy. Details here: https://bit.ly/3NGNPWZ

We are pleased to announce positive regulatory updates for our investigational product, the Viaskin® Peanut Patch, including guidance on a pathway for Accelerated Approval for toddlers ages 1-3 with #PeanutAllergy . Join our conference call at 5pm ET for more: https://bit.ly/4hfTfpC

Our CMO, Pharis Mohideen , participated in a panel at FARE Neighborhoods Day about using data & research to navigate the landscapes of our neighborhoods to create more equitable futures for those with #FoodAllergies . We're grateful for the opportunity to participate in inspiring dialogue to move toward a more inclusive and healthy future for all.

Our team had the pleasure of connecting with members of the #allergy community for Allergy & Asthma Network 's annual #CorporateCouncil meeting. It was great to come together and discuss ways to empower patients and create a healthier future for all.

🔬 Our innovative technology platform merges science and technology to change the way we think about #allergy treatment. It allows us to explore the potential of the Viaskin® patch and epicutaneous immunotherapy for children with #PeanutAllergy . Learn more here: https://bit.ly/4b5svUE

In case you missed it, KSTP Minnesota explores the development of our investigational pediatric #PeanutAllergy treatment with Dr. Doug McMahon of the Asthma & Allergy Center of Minnesota and our CMO, Dr. Pharis Mohideen, featuring insights from a mother of a peanut-allergic child. Watch here to learn more: https://bit.ly/4guSbhe

Don't miss our lunch symposium at this year's World Allergy Congress. We will discuss our work to advance our lead candidate for the treatment of #PeanutAllergy . Learn more about the congress here: https://bit.ly/3MO4ub1 World Allergy Organization

We are proud to share that we've completed screening for our VITESSE Phase 3 #ClinicalTrial for children ages 4-7 with a #PeanutAllergy . We look forward to further advancing our clinical development program. Read more in our press release: https://bit.ly/4gxNxiD

Metric
Company Name	DBV Technologies S.A.	Agios Pharmaceuticals, Inc.	Biotech 365	Enterome
Symbol	DBV	AGIO
MSH ID	COM:DBV-TECHNOLOGIES	COM:AGIOS	COM:BIOTECH-365	COM:ENTEROME
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology Business Services	Biopharmaceuticals
Country	FR	US	FR
Stage
Employee Count	105	383		51
Website	dbv-technologies.com	agios.com	biotech-365.com	enterome.com
LinkedIn	dbv-technologies
Founders

Metric
Market Cap	77.97M	2.47B
Enterprise Value
Monthly Web Traffic			68
Web Traffic Growth			-0.57
Valuation
Raised Capital

Metric
Revenue		26.82M
Revenue (LTM)
Revenue (NTM)
Gross Profit		17.32M
EBITDA		-384.86M
Operating Income		-391.49M
Net Income		-352.09M
EPS		-6.33
Diluted EPS		-6.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.84
Operating Profit Margin		-12.94
EBITDA Margin		-14.35
Net Profit Margin		-11.66
Return on Equity		-0.37
Return on Assets		-0.37
Return on Capital Employed		-0.45

COM:DBV-TECHNOLOGIES

DBV Technologies

Last Close

0.54

25/11 09:25

Market Cap

73.81M

Beta: -

Volume Today

40.67K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-23.82
P/B Ratio		1.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		96.00
EV Multiple		-4.30

Metric
Days Sales Outstanding		40.78
Days Payables Outstanding		1.64K
Days Inventory Outstanding		1.63K
Operating Cycle		1.66K
Cash Conversion Cycle		830.26
Asset Turnover		0.04

Metric
Operating Cash Flow		-296.06M
Free Cash Flow		-297.06M
Cash Flow to Debt		-4.11
Operating Cash Flow/Sales		-9.79
Free Cash Flow Yield		-0.23

Metric
Cash & Equivalents		88.20M
Accounts Receivable		-604K
Inventory		19.08M
Goodwill
Debt to Capitalization		0.09
Debt to Assets		0.07
Current Ratio		13.73
Quick Ratio		12.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		2.21
R&D to Revenue		13.47
SG&A to Revenue